JP2018537956A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537956A5
JP2018537956A5 JP2018517785A JP2018517785A JP2018537956A5 JP 2018537956 A5 JP2018537956 A5 JP 2018537956A5 JP 2018517785 A JP2018517785 A JP 2018517785A JP 2018517785 A JP2018517785 A JP 2018517785A JP 2018537956 A5 JP2018537956 A5 JP 2018537956A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
homology
trem2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517785A
Other languages
English (en)
Japanese (ja)
Other versions
JP7725185B2 (ja
JP2018537956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055828 external-priority patent/WO2017062672A2/en
Publication of JP2018537956A publication Critical patent/JP2018537956A/ja
Publication of JP2018537956A5 publication Critical patent/JP2018537956A5/ja
Priority to JP2023060952A priority Critical patent/JP2023093528A/ja
Application granted granted Critical
Publication of JP7725185B2 publication Critical patent/JP7725185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517785A 2015-10-06 2016-10-06 抗ｔｒｅｍ２抗体及びその使用方法 Active JP7725185B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060952A JP2023093528A (ja) 2015-10-06 2023-04-04 抗ｔｒｅｍ２抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562238044P 2015-10-06 2015-10-06
US62/238,044 2015-10-06
US201662369666P 2016-08-01 2016-08-01
US62/369,666 2016-08-01
PCT/US2016/055828 WO2017062672A2 (en) 2015-10-06 2016-10-06 Anti-trem2 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060952A Division JP2023093528A (ja) 2015-10-06 2023-04-04 抗ｔｒｅｍ２抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2018537956A JP2018537956A (ja) 2018-12-27
JP2018537956A5 true JP2018537956A5 (https=) 2019-11-21
JP7725185B2 JP7725185B2 (ja) 2025-08-19

Family

ID=57178515

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018517785A Active JP7725185B2 (ja) 2015-10-06 2016-10-06 抗ｔｒｅｍ２抗体及びその使用方法
JP2023060952A Pending JP2023093528A (ja) 2015-10-06 2023-04-04 抗ｔｒｅｍ２抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060952A Pending JP2023093528A (ja) 2015-10-06 2023-04-04 抗ｔｒｅｍ２抗体及びその使用方法

Country Status (9)

Country Link
US (2) US20190330335A1 (https=)
EP (1) EP3359569A2 (https=)
JP (2) JP7725185B2 (https=)
KR (1) KR20180068999A (https=)
CN (2) CN117069841A (https=)
AU (2) AU2016334051B2 (https=)
CA (1) CA2997960A1 (https=)
SG (1) SG10201912150TA (https=)
WO (1) WO2017062672A2 (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
EP3487886A2 (en) 2016-07-22 2019-05-29 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Trem2 cleavage modulators and uses thereof
JP7159188B2 (ja) * 2016-12-13 2022-10-24 アキリ・インタラクティヴ・ラブズ・インコーポレイテッド ナビゲーション課題を使用するバイオマーカーの識別およびナビゲーション課題を使用する治療のためのプラットフォーム
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018289428B2 (en) * 2017-06-21 2024-06-27 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells
JP2020530554A (ja) 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
BR112019022752A2 (pt) * 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
EP3697814A1 (en) * 2017-10-16 2020-08-26 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
WO2019118513A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
EP3794027A4 (en) * 2018-05-18 2022-02-09 MacroGenics, Inc. OPTIMIZED GP41 BINDING MOLECULES AND THEIR USES
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
EP3849598A4 (en) * 2018-09-11 2022-07-06 Washington University Anti-trem-2 agonist antibodies
CN121253826A (zh) * 2018-10-05 2026-01-02 西雅图儿童医院以西雅图儿童研究机构名义经营 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查
UY38407A (es) * 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
KR102156165B1 (ko) * 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN113302206A (zh) * 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
US12351629B2 (en) 2018-12-10 2025-07-08 Mor Research Applications Ltd. TREM2 antibodies and uses thereof
WO2020123664A1 (en) * 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
WO2020163817A1 (en) * 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau
PH12021552002A1 (en) * 2019-02-20 2022-09-19 Denali Therapeutics Inc Anti-trem2 antibodies and methods of use thereof
AU2020228660A1 (en) * 2019-02-28 2021-08-26 Inspirna, Inc. APOE genotyping in cancer prognostics and treatment
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
CN110320368A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7368624B2 (ja) * 2019-11-22 2023-10-24 イーライ リリー アンド カンパニー Ｔｒｅｍ２抗体およびそれらの使用
MX2022006073A (es) * 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
TWI890727B (zh) * 2020-01-13 2025-07-21 美商戴納立製藥公司 抗trem2 抗體及其使用方法
PE20221465A1 (es) * 2020-01-13 2022-09-21 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
CA3167851A1 (en) * 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
EP4126966A4 (en) 2020-03-31 2024-08-07 Seattle Children's Hospital d/b/a Seattle Children's Research Institute PROTEOMIC SCREENING FOR LYSOSOMAL STORAGE DISEASES
CN115298215A (zh) 2020-04-02 2022-11-04 西雅图儿童医院以西雅图儿童研究机构名义经营 特异性地结合与原发性免疫缺陷：维斯科特-奥尔德里奇综合征和x连锁无丙种球蛋白血症相关的肽的抗体
CN115667308A (zh) * 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
KR20230004726A (ko) * 2020-04-22 2023-01-06 아케소 바이오파마, 인크. 항-cd73/항-pd-1 이중특이항체 및 이의 용도
RS66984B1 (sr) * 2020-06-26 2025-07-31 Bioarctic Ab Antitela koja vezuju alfa-sinuklein protofibril
MX2023001546A (es) * 2020-08-05 2023-05-03 Vigil Neuroscience Inc Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2.
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
JP2023551542A (ja) 2020-11-30 2023-12-08 エニグマ バイオインテリジェンス，インコーポレイテッド アルツハイマー病の非侵襲的評価
AU2021392813A1 (en) * 2020-12-04 2023-06-29 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
WO2022159620A1 (en) * 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
CN112979795B (zh) * 2021-02-26 2022-07-08 深圳市亚辉龙生物科技股份有限公司 抗体组合产品及其在新冠肺炎检测中应用
EP4308586A1 (en) * 2021-03-19 2024-01-24 BicycleTX Limited Bicyclic peptide ligands specific for trem2
AU2022273303A1 (en) 2021-05-14 2023-11-02 Genentech, Inc. Agonists of trem2
WO2022245553A2 (en) * 2021-05-19 2022-11-24 Signablk, Inc. Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
CA3229327A1 (en) * 2021-08-20 2023-02-23 Aftab S. Karim Antibodies and antigen binding fragments against cd155 methods of use thereof
WO2023039450A2 (en) * 2021-09-07 2023-03-16 Duke University Compositions and methods for treatment of retinal degeneration
TW202334140A (zh) * 2021-11-09 2023-09-01 美商維佳神經科學有限公司 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法
JP2025503437A (ja) 2021-12-17 2025-02-04 デナリ セラピューティクス インコーポレイテッド ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド
EP4455275A4 (en) * 2021-12-22 2026-03-18 Univ Kagoshima MACROPHAGE PRODUCTION METHOD, DIFFERENCE-INDUCING AGENT, DIFFERENCE-INDUCING KIT, MACROPHAGE CULTIVATION METHOD, MACROPHAGE PROPAGATION-PROMOTING AGENT, MACROPHAGE PROLIFERATION-PROMOTING KIT, MACROPHAGE PROLIFERATION METHOD, AND MACROPHAGES
EP4463700A1 (en) * 2022-01-11 2024-11-20 Regeneron Pharmaceuticals, Inc. Triggering receptor expressed on myeloid cells 2 (trem2) variants and uses thereof in treating alzheimer's disease
US20230279130A1 (en) * 2022-01-14 2023-09-07 Qilu Puget Sound Biotherapeutics Corporation Anti-ccr8 antibodies
EP4482523A1 (en) 2022-02-23 2025-01-01 Alector LLC Methods of use of anti-trem2 antibodies
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
US20250289879A1 (en) * 2022-04-29 2025-09-18 The Children's Medical Center Corporation Therapeutic modulation of genes in myeloid lineage cells and uses thereof in ophthalmology
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
WO2024182318A2 (en) * 2023-02-28 2024-09-06 Kodiak Sciences Inc. Antibodies to htra1 and conjugates thereof
WO2024226569A1 (en) * 2023-04-24 2024-10-31 The Research Foundation For The State University Of New York Immunogenicity screening method
WO2024253424A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
CN119775421B (zh) * 2023-12-21 2025-10-31 华润生物医药有限公司 抗trem2抗体及其用途
WO2025194147A1 (en) * 2024-03-15 2025-09-18 The Children's Medical Center Corporation Therapeutic modulation of trem2 and uses thereof in retinal degeneration
US12545729B2 (en) 2024-06-27 2026-02-10 Mabwell Therapeutics, Inc. Anti-TREM2 agonist antibodies and antigen-binding fragments thereof that can increase levels of soluble TREM2 in serum and brain tissue

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途；関連試薬
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP2010540660A (ja) 2007-10-05 2010-12-24 ユニバーシティ オブ メリーランド，ボルチモア 哺乳類内の赤血球生成を刺激する新規の組成物および方法
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته

Similar Documents

Publication Publication Date Title
JP2018537956A5 (https=)
CN109311971B (zh) 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途
KR102562519B1 (ko) IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
CN109715663B (zh) 结合生长抑素受体2的异源二聚抗体
JP2017523814A5 (https=)
JP2019514347A5 (https=)
JP2019500014A5 (https=)
JP2018517401A5 (https=)
HRP20211980T1 (hr) Protutijela protiv sortilina i postupci njihove upotrebe
JP2018525999A5 (https=)
JP2024521131A (ja) 操作されたポリペプチド
US20220227867A1 (en) ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
WO2023164640A1 (en) Anti-cd28 x anti-trop2 antibodies
WO2023164627A1 (en) Anti-cd28 x anti-msln antibodies
WO2024192308A2 (en) Anti-cd28 compositions
CA3229822A1 (en) Cd33 x v?2 multispecific antibodies for the treatment of cancer
WO2025111585A1 (en) Engineered bispecific molecules and methods of use
TW202525853A (zh) 抗ｃｄ２０ｘ抗ｃｄ２８組合療法
WO2024216226A1 (en) Anti-cd28 x anti-enpp3 antibodies
Lindhofer et al. Trifunctional Triomab® antibodies for cancer therapy
US20250304683A1 (en) Engineered bispecific molecules and methods of use
US20250304684A1 (en) Engineered bispecific molecules and methods of use
WO2026050570A1 (en) Engineered protein constructs targeting siglec-8 and cd117
WO2026064545A1 (en) Engineered tl1a targeting regions and methods of use
WO2025090973A2 (en) Anti-trop2 x anti-pdl1 x anti-cd28 antibodies